All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The standard of care for patients with newly-diagnosed, advanced-stage, Hodgkin lymphoma (HL), is treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). An alternative first-line regimen is escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP), which has been associated with improved efficacy but also increased toxicity when compared to ABVD.1 Therefore, ABVD treatment is preferred but not all patients are responsive to this regimen. Positron emission tomography (PET) scan can be used to identify patients that are not responsive to ABVD treatment and can be switched to eBEACOPP. After two cycles of ABVD, PET-positive scans seem highly predictive of treatment failure with ABVD.
The phase II Southwest Oncology Group (SWOG) S0816 trial (NCT00822120) investigated the long-term outcomes in patients who received response-adapted therapy based on PET imaging. Patients were treated with two cycles of ABVD and then a PET scan (PET2) was performed to evaluate the efficacy of the treatment. Those achieving a complete response (CR) on PET2 continued with four additional cycles of ABVD, while those who didn’t were switched to eBEACOPP for six cycles.
Results of SWOG S0816 with a median of 3.3 years follow-up have been previously published by Oliver W. Press, Fred Hutchinson Cancer Research Center, Seattle, US and the University of Washington, Seattle, US, and colleagues. The primary endpoints were reached with a two-year progression-free survival (PFS) of 79% for all patients, 82% for PET2-negative patients and 64% for PET2-positive patients. The estimated two-year Overall Survival (OS) was 98%.2 In a paper published in Blood on the 10th of October 2019, Deborah M. Stephens, University of Utah, Salt Lake City, US, and colleagues presented a five-year follow-up of the SWOG S0816 trial.3
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox